Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

A new prevention paradox: the trade-off between reducing incentives for risk selection and increasing the incentives for prevention for health insurers.

Kanters TA, Brouwer WB, van Vliet RC, van Baal PH, Polder JJ.

Soc Sci Med. 2013 Jan;76(1):150-8. doi: 10.1016/j.socscimed.2012.10.019. Epub 2012 Nov 3.

PMID:
23182593
2.

Optimal cost reimbursement of health insurers to reduce risk selection.

Kifmann M, Lorenz N.

Health Econ. 2011 May;20(5):532-52. doi: 10.1002/hec.1614.

PMID:
20572200
3.

Improving risk equalization using multiple-year high cost as a health indicator.

van Kleef RC, van Vliet RC.

Med Care. 2012 Feb;50(2):140-4. doi: 10.1097/MLR.0b013e31822ebf8b.

PMID:
21945975
4.

Improving the prediction model used in risk equalization: cost and diagnostic information from multiple prior years.

van Veen SH, van Kleef RC, van de Ven WP, van Vliet RC.

Eur J Health Econ. 2015 Mar;16(2):201-18. doi: 10.1007/s10198-014-0567-7. Epub 2014 Feb 12.

PMID:
24519402
5.

Risk equalization in The Netherlands: an empirical evaluation.

Van Kleef RC, Van Vliet RC, Van de Ven WP.

Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(6):829-39. doi: 10.1586/14737167.2013.842127. Epub 2013 Nov 1.

PMID:
24175733
6.

Diagnoses-based cost groups in the Dutch risk-equalization model: the effects of including outpatient diagnoses.

van Kleef RC, van Vliet RC, van Rooijen EM.

Health Policy. 2014 Mar;115(1):52-9. doi: 10.1016/j.healthpol.2013.07.005. Epub 2013 Jul 31.

PMID:
23910732
7.

Risk selection in a regulated health insurance market: a review of the concept, possibilities and effects.

van Kleef RC, van de Ven WP, van Vliet RC.

Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(6):743-52. doi: 10.1586/14737167.2013.841546. Review.

PMID:
24219050
8.
9.

Managing risk selection incentives in health sector reforms.

Puig-Junoy J.

Int J Health Plann Manage. 1999 Oct-Dec;14(4):287-311. Review.

PMID:
11184915
10.

Lifetime medical costs of obesity: prevention no cure for increasing health expenditure.

van Baal PH, Polder JJ, de Wit GA, Hoogenveen RT, Feenstra TL, Boshuizen HC, Engelfriet PM, Brouwer WB.

PLoS Med. 2008 Feb;5(2):e29. doi: 10.1371/journal.pmed.0050029.

11.

Healthcare costs and obesity prevention: drug costs and other sector-specific consequences.

Rappange DR, Brouwer WB, Hoogenveen RT, Van Baal PH.

Pharmacoeconomics. 2009;27(12):1031-44. doi: 10.2165/11319900-000000000-00000.

PMID:
19908927
12.

Mandatory high-risk pooling: an approach to reducing incentives for cream skimming.

van Barneveld EM, van Vliet RC, van de Ven WP.

Inquiry. 1996 Summer;33(2):133-43.

PMID:
8675277
13.

[Pay for performance in Colombian healthcare].

Gorbanev I, Cortes A, Torres S, Yepes F.

Rev Salud Publica (Bogota). 2011 Oct;13(5):727-36. Spanish.

14.
15.

Risk adjustment in health insurance and its long-term effectiveness.

Beck K, Trottmann M, Zweifel P.

J Health Econ. 2010 Jul;29(4):489-98. doi: 10.1016/j.jhealeco.2010.03.009. Epub 2010 Apr 2.

PMID:
20434784
16.

[Pay for performance explained by transaction costs theory].

Gorbaneff Y, Cortes A, Torres S, Yepes F.

Gac Sanit. 2011 Nov-Dec;25(6):450-3. doi: 10.1016/j.gaceta.2011.07.002. Epub 2011 Sep 13. Spanish.

17.

Capping risk adjustment?

Eugster P, Sennhauser M, Zweifel P.

J Health Econ. 2010 Jul;29(4):499-507. doi: 10.1016/j.jhealeco.2010.04.001. Epub 2010 Apr 18.

PMID:
20462647
18.

Towards a capitation formula for competing health insurers. An empirical analysis.

van Vliet RC, van de Ven WP.

Soc Sci Med. 1992 May;34(9):1035-48.

PMID:
1631603
19.

A limited-sample benchmark approach to assess and improve the performance of risk equalization models.

Stam PJ, van Vliet RC, van de Ven WP.

J Health Econ. 2010 May;29(3):426-37. doi: 10.1016/j.jhealeco.2010.02.001. Epub 2010 Feb 17.

PMID:
20304510
20.
Items per page

Supplemental Content

Write to the Help Desk